124782-95-2Relevant articles and documents
BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD
-
Page/Page column 296; 297, (2020/07/14)
The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.
Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1
Lee, Byoung Se,Chu, Soyoung,Lee, Byung Chul,Chi, Dae Yoon,Choe, Yearn Seong,Jeong, Kyung Ja,Jin, Changbae
, p. 1559 - 1562 (2007/10/03)
6-Nitroquipazine has been known as one of the most potent and selective inhibitors of serotonin transporter in vitro and in vivo. Nine derivatives of 6-nitroquipazine were synthesized and tested for their potential abilities to displace [3H]citalopram binding to the rat cortical membranes. (C) 2000 Elsevier Science Ltd. All rights reserved.